SourceBio International (LON:SBS) has made a huge impact on its return to public markets. It reported a 139% rise in fiscal 2020 (FY20) reported revenues to £50.7mln from £21.2mln and underlying earnings (EBITDA) of £14mln, vs £3mln in FY19. Proactive Analyst Emma Ulker explains why this growth has been driven largely on its rapid mobilisation of resources to create a new fourth division; infectious disease testing services.
Proactive Analyst Emma Ulker talks about lab services and products provider Source Bio
Quick facts: SourceBio International PLC
Price: 188.055 GBX
Market Cap: £139.5 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of SourceBio International PLC named herein, including the promotion by the Company of SourceBio International PLC in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE